Disclosure Plus

KPM TECH CO., LTD. Decides on 22.5 Billion Won Third-Party Private Placement

Park Sun-Yeop
2026-07-03 16:47:16
[E-Daily Reporter Park Sun-Yeop ] KPM TECH CO., LTD.(042040)announced on the 3rd that it has decided to conduct a third-party private placement worth 22.4999 billion won targeting its largest shareholder, Telcon RF Pharmaceuticals.
A total of 6,200,055 common shares will be issued. The issue price is 3,629 won per share, and the new shares are scheduled to be listed on the 27th. The payment date is the 13th.
Of the funds raised, 8 billion won will be used to repay debt, and 14.4999 billion won will be used to acquire securities of other companies. The funds for acquiring securities of other companies are planned to be used to acquire shares of NUON.
The proceeds from this new share issuance will be paid through a combination of a cash payment of 14.4999 billion won from Telcon RF Pharmaceuticals and a substitute payment of 8 billion won in the form of borrowed funds. The company borrowed 6 billion won from Telcon RF Pharmaceuticals on March 31 and 2 billion won on April 27.
Prior to the capital increase, KPM TECH CO., LTD.’s total number of issued shares stood at 2,470,936 common shares. The new shares issued through this capital increase will be subject to a one-year lock-up period starting from the date of certificate issuance.

Economy

Corporation

IT·Science

Economy

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
2026-11-21 10:04:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

Penetrium Bioscience and AprilBio Rally as AriBio-Linked Stocks Diverge [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…
2026-11-21 08:17:02